Advanced search
Publication Cover
Cancer Investigation Volume 14, 1996 - Issue 6
Submit an article Journal homepage
25
Views
38
CrossRef citations to date
0
Altmetric
Original Article

Lack of Correlation Between Prostate-Specific Antigen and the Presence of Measurable Soft Tissue Metastases in Hormone-Refractory Prostate Cancer

William D. Figg Clinical Pharmacology Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
,
Kara Ammerman Clinical Pharmacology Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
,
Nicholas Patronas Diagnostic Radiology Department and Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
,
Seth M. Steinberg Biostatistics and Data Management Section, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
,
Ronald G. Walls Clinical Pharmacology Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
,
Nancy Dawson Clinical Pharmacology Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
,
Eddie Reed Clinical Pharmacology Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
&
Oliver Sartor Clinical Pharmacology Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
 show all
Pages 513-517 | Published online: 11 Jun 2009

Citations (38)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Emma Cattell, Ana Arance & Mark Middleton. (2002) Assessing outcomes in palliative chemotherapy. Expert Opinion on Pharmacotherapy 3:6, pages 693-700.
Read now
Eric H Holmes. (2001) PSMA specific antibodies and their diagnostic and therapeutic use. Expert Opinion on Investigational Drugs 10:3, pages 511-519.
Read now
A. Rydh, K. Riklund Åhlström, A. Larsson, L. Johansson, Damber J.-E.R. Tomiç & Hietala S.-O.. (2000) QUANTITATIVE BONE SCINTIGRAPHY: A methodological evaluation in prostate cancer. Acta Radiologica 41:2, pages 183-188.
Read now

Articles from other publishers (35)

Fred Saad, Johann de Bono, Neal Shore, Karim Fizazi, Yohann Loriot, Mohammad Hirmand, Billy Franks, Gabriel P. Haas & Howard I. Scher. (2015) Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial. European Urology 67:2, pages 223-230.
Crossref
Fabio A. Schutz, Antonio C. Buzaid & Oliver Sartor. (2014) Taxanes in the management of metastatic castration-resistant prostate cancer: Efficacy and management of toxicity. Critical Reviews in Oncology/Hematology 91:3, pages 248-256.
Crossref
Jorge A. Garcia & Robert Dreicer. 2014. Management of Castration Resistant Prostate Cancer. Management of Castration Resistant Prostate Cancer 187 199 .
C O'Hanlon Brown & J Waxman. (2012) Current management of prostate cancer: dilemmas and trials. The British Journal of Radiology 85:special_issue_1, pages S28-S40.
Crossref
Fernando C. Maluf, Oren Smaletz & Daniel Herchenhorn. (2012) Castration-resistant prostate cancer: systemic therapy in 2012. Clinics 67:4, pages 389-394.
Crossref
Marijo Bilusic, Christopher Heery & Ravi A. Madan. (2011) Immunotherapy in prostate cancer: Emerging strategies against a formidable foe. Vaccine 29:38, pages 6485-6497.
Crossref
Joseph D. Khoury, Dorothy M. Adcock, Fanny Chan, James T. Symanowski, Stefan Tiefenbacher, Oscar Goodman, Lazara Paz, Yupo Ma, David C. Ward, Nicholas J. Vogelzang & Louis M. Fink. (2010) Increases in Quantitative D-Dimer Levels Correlate With Progressive Disease Better Than Circulating Tumor Cell Counts in Patients With Refractory Prostate Cancer. American Journal of Clinical Pathology 134:6, pages 964-969.
Crossref
Oscar B. GoodmanJr.Jr., Louis M. Fink, James T. Symanowski, Bryan Wong, Beth Grobaski, David Pomerantz, Yupo Ma, David C. Ward & Nicholas J. Vogelzang. (2009) Circulating Tumor Cells in Patients with Castration-Resistant Prostate Cancer Baseline Values and Correlation with Prognostic Factors. Cancer Epidemiology, Biomarkers & Prevention 18:6, pages 1904-1913.
Crossref
Shenhong L. Wu, Elizabeth Jones, James L. Gulley, Philip M. Arlen, Clara C. Chen, William D. Figg & William L. Dahut. (2007) Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone. BJU International 99:3, pages 525-528.
Crossref
Paula Scullin, Joe M. O’Sullivan & Christopher C. Parker. 2007. Metastasis of Prostate Cancer. Metastasis of Prostate Cancer 309 335 .
Mark T Fleming, Michael J Morris, Glenn Heller & Howard I Scher. (2006) Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nature Clinical Practice Oncology 3:12, pages 658-667.
Crossref
Michael J. Morris, Howard I. Scher, Neeta Pandit-Taksar, Chaitanya Divgi & Steven Larson. 2006. Prostate Cancer: Translational and Emerging Therapies. Prostate Cancer: Translational and Emerging Therapies 291 313 .
Howard I. Scher, Michael J. Morris, William K. Kelly, Lawrence H. Schwartz & Glenn Heller. (2005) Prostate Cancer Clinical Trial End Points: “RECIST”ing a Step Backwards. Clinical Cancer Research 11:14, pages 5223-5232.
Crossref
A J Birtle, J C Newby & S J Harland. (2004) Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer. British Journal of Cancer 91:8, pages 1472-1476.
Crossref
Navjeet Gandhok & Oliver Sartor. 2004. Management of Prostate Cancer. Management of Prostate Cancer 589 606 .
Elizabeth C Kent & Maha H.A Hussain. (2003) The patient with hormone-refractory prostate cancer: determining who, when, and how to treat. Urology 62, pages 134-140.
Crossref
D.S. ErnstI.F. TannockE.W. WinquistP.M. VennerL. ReynoM.J. MooreK. ChiK. DingC. ElliottW. Parulekar. (2003) Randomized, Double-Blind, Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone and Placebo in Patients With Hormone-Refractory Prostate Cancer and Pain. Journal of Clinical Oncology 21:17, pages 3335-3342.
Crossref
Masanori Noguchi, Jyunro Yahara & Shinshi Noda. (2003) Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. Urology 61:5, pages 993-998.
Crossref
Paolo TralongoRoberto BollinaRosanna AielloAnna Di MariGiovanni MoruzziGianni Beretta, Gaetano MauceriGianfranco Conti. (2018) Vinorelbine and Prednisone in older Cancer Patients with Hormone-Refractory Metastatic Prostate Cancer a Phase II Study. Tumori Journal 89:1, pages 26-30.
Crossref
Sebastien J. Hotte, Eric W. Winquist, Larry Stitt, Sylvia M. Wilson & Ann F. Chambers. (2002) Plasma osteopontin. Cancer 95:3, pages 506-512.
Crossref
Julie A. Kish, Raviender Bukkapatnam & Felipe Palazzo. (2017) The Treatment Challenge of Hormone-Refractory Prostate Cancer. Cancer Control 8:6, pages 487-495.
Crossref
D.B Sodee, N Malguria, P Faulhaber, M.I Resnick, J Albert & G Bakale. (2000) Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. Urology 56:6, pages 988-993.
Crossref
William K. Oh. (2000) Chemotherapy for patients with advanced prostate carcinoma. Cancer 88:S12, pages 3015-3021.
Crossref
Karin B. Olson & Kenneth J. Pienta. (2000) Recent advances in chemotherapy for advanced prostate cancer. Current Urology Reports 1:1, pages 48-56.
Crossref
Abdel-Aziz A. Elgamal, Eric H. Holmes, Sai L. Su, William T. Tino, Sheila J. Simmons, Mary Peterson, Thomas G. Greene, Alton L. Boynton & Gerald P. Murphy. (2000) Prostate-specific membrane antigen (PSMA): Current benefits and future value. Seminars in Surgical Oncology 18:1, pages 10-16.
Crossref
Glenn J. BubleyMichael CarducciWilliam DahutNancy DawsonDanai DalianiMario EisenbergerWilliam D. FiggBoris FreidlinSusan HalabiGary HudesMaha HussainRichard KaplanCharles MyersWilliam OhDaniel P. PetrylakEddie ReedBruce RothOliver SartorHoward ScherJonathan SimonsVickie SinibaldiEric J. SmallMatthew R. SmithDonald L. TrumpRobin VollmerGeorge Wilding. (1999) Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group. Journal of Clinical Oncology 17:11, pages 3461-3467.
Crossref
Darrel E. Drachenberg, Abdel-Aziz A. Elgamal, Ron Rowbotham, Mary Peterson & Gerald P. Murphy. (1999) Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. The Prostate 41:2, pages 127-133.
Crossref
B.A. Tjoa, S.J. Simmons, A. Elgamal, M. Rogers, H. Ragde, G.M. Kenny, M.J. Troychak, A.L. Boynton & G.P. Murphy. (1999) Follow-up evaluation of a phase II prostate cancer vaccine trial. The Prostate 40:2, pages 125-129.
Crossref
Benjamin A. Tjoa, Abdel-Aziz A. Elgamal & Gerald P. Murphy. (1999) VACCINE THERAPY FOR PROSTATE CANCER. Urologic Clinics of North America 26:2, pages 365-374.
Crossref
Michael A. Carducci, Theodore L. DeWeese & Joel B. Nelson. (1999) PROSTATE-SPECIFIC ANTIGEN AND OTHER MARKERS OF THERAPEUTIC RESPONSE. Urologic Clinics of North America 26:2, pages 291-302.
Crossref
J Horti, S C Dixon, C J Logothetis, Y Guo, E Reed & W D Figg. (1999) Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor. British Journal of Cancer 79:9-10, pages 1588-1593.
Crossref
Oliver Sartor & William D. Figg. 1999. The Oncobiology of the Prostate. The Oncobiology of the Prostate 235 255 .
WILLIAM K. OH & PHILIP W. KANTOFF. (1998) MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER. The Journal of Urology, pages 1220-1229.
Crossref
WILLIAM K. OH & PHILIP W. KANTOFF. (1998) MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS. The Journal of Urology 160:4, pages 1220-1229.
Crossref
S. Modoni, E. Calò, G. Nardella, G. Ritrovato & V. Frusciante. (2018) PSA and Bone Scintigraphy. The International Journal of Biological Markers 12:4, pages 158-161.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.